Sickle Cell Disease Therapeutics
Europe · 1 shared keyword
Updated
Reviewed by Vidhi Upadhyay
Europe Lysosomal Storage Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Disease, Treatment, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.42 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.07 Bn | — | — |
| 2025 (base) | $2.19 Bn | +$118.2 Mn | — |
| 2026 (forecast) | $2.32 Bn | +$125.0 Mn | +5.7% |
| 2027 (forecast) | $2.45 Bn | +$132.1 Mn | +11.7% |
| 2028 (forecast) | $2.59 Bn | +$139.6 Mn | +18.1% |
| 2029 (forecast) | $2.74 Bn | +$147.6 Mn | +24.8% |
| 2030 (forecast) | $2.89 Bn | +$156.0 Mn | +31.9% |
| 2031 (forecast) | $3.06 Bn | +$164.9 Mn | +39.5% |
| 2032 (forecast) | $3.23 Bn | +$174.3 Mn | +47.4% |
| 2033 (forecast) | $3.42 Bn | +$184.2 Mn | +55.8% |
| 2034 (forecast) | $3.61 Bn | +$194.7 Mn | +64.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.19 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $3.61 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Disease, treatment and end user (see all) |
| Key players | Sanofi, Takeda Pharmaceutical Company Ltd, BioMarin, Amicus Therapeutics, Chiesi (see all) |
| Regulator in Europe | EMASource: European Medicines Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Lysosomal storage disease treatments help people with rare inherited conditions where cells cannot break down certain substances.
Key segments of the lysosomal Storage Disease Treatment market include disease (Gaucher, Fabry and Pompe) and treatment (Enzyme Replacement, Substrate Reduction and Gene Therapy).
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the lysosomal Storage Disease Treatment market. More countries now have national rare disease plans.
Newborn genome screening, gene therapies and access programmes in emerging markets give the lysosomal Storage Disease Treatment market strong growth.
Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the lysosomal Storage Disease Treatment market.
The lysosomal Storage Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], CBG-MEB (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15]
[1] European Medicines Agency. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.
[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.
[10] Swissmedic. Checked 19 Nov 2026.
[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.
[12] Danish Medicines Agency. Checked 19 Nov 2026.
[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.
[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.
[15] European Commission, health technology assessment. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lysosomal Storage Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
What doctors and scientists are doing in Lysosomal Storage Disease Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Digital Health · Europe
Healthcare Services · Europe
Healthcare Services · Europe
Medical Devices · Europe
Digital Health · Europe
Medical Devices · Europe